Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

OBJECTIVE: To estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monotherapy in treatment-naïve patients with type 2 diabetes mellitus (T2DM) in China. METHODS: The Cardiff Diabetes Model, an economic model designed to evaluate the cost-effectiveness of comparator therapie...

ver descrição completa

Detalhes bibliográficos
Principais autores: Gu, Shuyan, Mu, Yiming, Zhai, Suodi, Zeng, Yuhang, Zhen, Xuemei, Dong, Hengjin
Formato: Online Atigo Texto
Idioma:English
Publicado em: Public Library of Science 2016
Assuntos:
Research Article
Acesso em linha:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091768/
https://www.ncbi.nlm.nih.gov/pubmed/27806087
http://dx.doi.org/10.1371/journal.pone.0165629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091768/
https://www.ncbi.nlm.nih.gov/pubmed/27806087
http://dx.doi.org/10.1371/journal.pone.0165629

Registros relacionados